CN101591653A - 低表达cyp7a1的肝细胞及其构建方法 - Google Patents
低表达cyp7a1的肝细胞及其构建方法 Download PDFInfo
- Publication number
- CN101591653A CN101591653A CNA2008100974728A CN200810097472A CN101591653A CN 101591653 A CN101591653 A CN 101591653A CN A2008100974728 A CNA2008100974728 A CN A2008100974728A CN 200810097472 A CN200810097472 A CN 200810097472A CN 101591653 A CN101591653 A CN 101591653A
- Authority
- CN
- China
- Prior art keywords
- cyp7a1
- sequence
- seq
- sirna
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100974728A CN101591653B (zh) | 2008-05-27 | 2008-05-27 | 低表达cyp7a1的肝细胞及其构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100974728A CN101591653B (zh) | 2008-05-27 | 2008-05-27 | 低表达cyp7a1的肝细胞及其构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101591653A true CN101591653A (zh) | 2009-12-02 |
CN101591653B CN101591653B (zh) | 2013-07-31 |
Family
ID=41406533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100974728A Expired - Fee Related CN101591653B (zh) | 2008-05-27 | 2008-05-27 | 低表达cyp7a1的肝细胞及其构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101591653B (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013113252A1 (zh) * | 2012-02-02 | 2013-08-08 | 北京大学 | 一种调控cyp基因表达水平的方法及其应用 |
WO2018044778A1 (en) * | 2016-08-29 | 2018-03-08 | NGM Biopharmaceuticals, Inc | Methods for treatment of bile acid-related disorders |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
CN110106250A (zh) * | 2019-05-28 | 2019-08-09 | 中国农业大学 | 与奶牛围产期代谢疾病抗性相关的分子标记及应用 |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10413590B2 (en) | 2011-07-01 | 2019-09-17 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US10758590B2 (en) | 2012-11-28 | 2020-09-01 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes |
US11066454B2 (en) | 2012-11-28 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US11103554B2 (en) | 2012-12-27 | 2021-08-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
US11564972B2 (en) | 2012-12-27 | 2023-01-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0648841B1 (en) * | 1993-10-13 | 2001-09-19 | Northeastern Ohio Universities | Genomic DNA of human Cholesterol 7alpha-hydroxylase and methods for using it |
CN1954826A (zh) * | 2005-10-26 | 2007-05-02 | 上海生物芯片有限公司 | 银杏叶提取物在降低胆固醇方面的用途 |
-
2008
- 2008-05-27 CN CN2008100974728A patent/CN101591653B/zh not_active Expired - Fee Related
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10413590B2 (en) | 2011-07-01 | 2019-09-17 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject |
US11065302B2 (en) | 2011-07-01 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising fusion variants of FGF19 polypeptides |
WO2013113252A1 (zh) * | 2012-02-02 | 2013-08-08 | 北京大学 | 一种调控cyp基因表达水平的方法及其应用 |
US10758590B2 (en) | 2012-11-28 | 2020-09-01 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes |
US11066454B2 (en) | 2012-11-28 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US11564972B2 (en) | 2012-12-27 | 2023-01-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject |
US11103554B2 (en) | 2012-12-27 | 2021-08-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US11241481B2 (en) | 2014-06-16 | 2022-02-08 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US11141460B2 (en) | 2014-11-07 | 2021-10-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
WO2018044778A1 (en) * | 2016-08-29 | 2018-03-08 | NGM Biopharmaceuticals, Inc | Methods for treatment of bile acid-related disorders |
CN110106250B (zh) * | 2019-05-28 | 2020-11-27 | 中国农业大学 | 与奶牛围产期代谢疾病抗性相关的分子标记及应用 |
CN110106250A (zh) * | 2019-05-28 | 2019-08-09 | 中国农业大学 | 与奶牛围产期代谢疾病抗性相关的分子标记及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101591653B (zh) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101591653A (zh) | 低表达cyp7a1的肝细胞及其构建方法 | |
CN102382801B (zh) | 蛋白去乙酰化酶sirt1在促进间充质干细胞增殖与延缓衰老中的应用 | |
CN101117625A (zh) | 诱导间充质干细胞和脂肪干细胞分化为神经元的方法及其专用培养基 | |
CN108165549B (zh) | 人工环状rna的通用表达框架及其应用 | |
CN104805120A (zh) | 一种shRNA-Ago2共表达慢病毒RNAi载体、重组质粒及其构建方法 | |
Wang et al. | CRISPR-Cas9 HDR system enhances AQP1 gene expression | |
JP2022514955A (ja) | ウィスコット・アルドリッチ症候群の造血幹細胞遺伝子治療 | |
CN101418285A (zh) | 诱导肝卵圆细胞向胆管细胞分化的方法及其专用培养基 | |
CN103305596B (zh) | 人rnf138基因的用途及其相关药物 | |
CN105200059A (zh) | 靶向抑制小鼠UCP2基因表达的siRNA及其表达载体的构建 | |
Vaidyanathan et al. | Highly efficient repair of the ΔF508 mutation in airway stem cells of cystic fibrosis patients with functional rescue of the differentiated epithelia | |
CN111235150B (zh) | 用于抑制非洲猪瘟病毒复制的shRNA及其用途 | |
CN102229928B (zh) | 人rbbp6基因的小干扰rna及其应用 | |
CN104225619B (zh) | 人ilk基因治疗肿瘤的用途及其相关药物 | |
CN103421884B (zh) | 人fzr1基因的用途及其相关药物 | |
CN101624596B (zh) | 一种靶向c-myc癌基因的外指引序列 | |
Moore-Rigdon et al. | Preferences for the selection of unique tRNA primers revealed from analysis of HIV-1 replication in peripheral blood mononuclear cells | |
Fahrbach et al. | Role of SV40 ST antigen in the persistent infection of mesothelial cells | |
CN103695427A (zh) | 用于敲低vps11的小分子干扰rna、重组载体及其应用 | |
EP4023229A1 (en) | Sirna capable of inhibiting expression of mcm7 gene, composition, and application thereof | |
CN114958855B (zh) | 一种促内皮细胞凋亡的siRNA及SIRT6低表达细胞系 | |
WO2023145884A1 (ja) | SARS-CoV-2由来ポリヌクレオチド及びその使用 | |
CN103301474B (zh) | 人rnf40基因的用途及其相关药物 | |
CN109929877A (zh) | Hmgcr基因在提高lv包装效率和感染力中的应用 | |
CN116144707A (zh) | 一种过表达hs3st5基因的试剂在促进病毒感染中的应用及重组cho-k1细胞系 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Pei Xuetao Inventor after: Zheng Jichun Inventor after: Wang Wenfang Inventor after: Yue Wen Inventor after: Shi Wei Inventor after: Yao Hailei Inventor after: Chen Lin Inventor after: Nan Xue Inventor after: Pei Haiyun Inventor before: Pei Xuetao Inventor before: Zheng Jichun Inventor before: Yue Wen Inventor before: Shi Wei |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: PEI XUETAO ZHENG JICHUN YUE WEN SHI WEI TO: PEI XUETAO ZHENG JICHUN WANG YUNFANG YUE WEN SHI WEI YAO HAILEI CHEN LIN NAN XUE PEI HAIYUN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130731 Termination date: 20140527 |